Clinical and Economic Aspects of KRAS Mutational Status as Predictor for Epidermal Growth Factor Receptor Inhibitor Therapy in Metastatic Colorectal Cancer Patients

Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients

(2011) Robert Königsberg et al.   ACTA ONCOLOGICA

Circulating tumor cells in metastatic colorectal cancer: Efficacy and feasibility of different enrichment methods

(2010) Robert Königsberg et al.   CANCER LETTERS

The Evolving Role of Monoclonal Antibodies in Colorectal Cancer: Early Presumptions and Impact on Clinical Trial Development

(2010) C. Eng   ONCOLOGIST

Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors

(2009) E. E. Mancl et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer

(2009) K.-L. G. Spindler et al.   ANNALS OF ONCOLOGY

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

(2009) Salvatore Siena et al.   JNCI-Journal of the National Cancer Institute

Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial

(2009) N. Mittmann et al.   JNCI-Journal of the National Cancer Institute

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

KRAS mutations predict response to EGFR inhibitors

(2008) Mitch Raponi et al.   CURRENT OPINION IN PHARMACOLOGY

KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

(2008) Astrid Lièvre et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

(2008) Carsten Bokemeyer et al.   JOURNAL OF CLINICAL ONCOLOGY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE